Clinical characteristics of alpha-fetoprotein-negative hepatic carcinoma patients：a study of 102 consecutive cases

Li Li,Jinglong Chen,Xiangyi Wang,Wendong Li,Xiaoyan Ding,Wei Sun,Xiaodi Guo,Yanjun Shen,Shasha Sun

DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2016.08.004

2016-01-01

Abstract:ObjectiveThis study was designed to investigate the clinical characteristics, biological behavior and prognosis of AFP negative primary hepatic carcinoma (PHC) patients.MethodsClinical data of 102 AFP negative primary hepatic carcinoma patients including risk factors, clinical manifestations, laboratory and imaging examinations, pathologic findings, modality of treatment and prognosis were collected to do retrospective analysis.ResultsAFP-negative PHC patients were male predominant, and the ratio of male to female was 5.38∶1. The median age of onset was 60 years. 83.3% patients were HbsAg positive, 68.6% patients were complicated with liver cirrhosis, and 76.5% patients were Barcelona Clinic Liver Cancer (BCLC) stage 0-A. Patients with treatment indications were given palliative or radical transcatheter arterial chemoembolization (TACE) or combined with CT-guiding percutaneous radiofrequency ablation (RFA). Until October 31, 2015, followed up for 41 to 82 months, the 1, 2, 3 year survival rate were 96.7%, 90.2% and 82.6%, respectively. AFP level increased during follow-up in 14 patients, which related with shorter survival. The change of helper T cell had statistical significance compared with AFP negative patients (P<0.05).ConclusionPatients with AFP negative primary hepatic carcinoma showed earlier stage in the first episode and better prognosis. AFP level increasing during&nbsp;follow-up is related with disease progression and shorter survival.